诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

交易中 05-03 15:47:08

5.330

+0.090

+1.72%

最高5.380	最低5.160	成交量129.11万
今开5.240	昨收5.240	日振幅4.20%
总市值93.95亿	流通市值93.95亿	总股本17.63亿
成交额684.95万	换手率0.07%	流通股本17.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":5.33,"timestamp":1714722425416,"preClose":5.24,"halted":0,"volume":1291080,"delay":0,"floatShares":1762582452,"shares":1762582452,"eps":-0.4015072,"marketStatus":"交易中","marketStatusCode":2,"change":0.09,"latestTime":"05-03 15:47:08","open":5.24,"high":5.38,"low":5.16,"amount":6849549,"amplitude":0.041985,"askPrice":5.35,"askSize":47000,"bidPrice":5.33,"bidSize":37000,"shortable":3,"etf":0,"ttmEps":-0.4015072069536942,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714723800000},"adr":0,"listingDate":1584892800000,"adjPreClose":5.24,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.479571,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":8.66,"timestamp":1714460400000,"preClose":8.55,"halted":0,"volume":3273792,"delay":0,"premium":"-43.28"}},"requestUrl":"/m/hq/s/09969/tweets","defaultTab":"tweets","newsList":[{"id":"2432644950","title":"诺诚健华(09969)股价显著上升14.471%，现价港币$5.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2432644950","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432644950?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:09","pubTimestamp":1714633740,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午03:09比前收市价显著上升14.471%，现股价为港币$5.3。至目前为止，今日最高价为$5.3，而最低价为$4.56。总成交量为170.472万股，总成交金额为港币$865.942万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405024725/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432643377","title":"港股异动 | 基石药业-B(02616)涨超26%领涨创新药概念 ASCO催化行情 机构看好政策+医保边际向上","url":"https://stock-news.laohu8.com/highlight/detail?id=2432643377","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432643377?lang=zh_cn&edition=full","pubTime":"2024-05-02 13:56","pubTimestamp":1714629376,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股表现强势，截至发稿，基石药业-B涨26.14%，报1.11港元；康希诺生物涨16.91%，报20.95港元；加科思-B涨14.2%，报1.93港元；诺诚健华涨12.31%，报5.2港元；荣昌生物涨10.2%，报30.8港元。浙商证券指出，2023年创新药医保谈判结果高成功率及温和降幅，体现出政策对创新药倾斜与支持，我们期待更多的创新药行业规范化以及支持的政策推进。创新药已形成较为稳定的谈判节奏和价格预期，我们持续看好创新药行业中长期的投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116861.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432769493","title":"诺诚健华盘中异动 早盘快速上涨5.40%报4.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432769493","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432769493?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:44","pubTimestamp":1714617848,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘10时44分，诺诚健华股票出现异动，股价大幅上涨5.40%。截至发稿，该股报4.880港元/股，成交量27.4721万股，换手率0.02%，振幅6.91%。诺诚健华股票所在的生物技术行业中，整体涨幅为0.56%。消息层面，截至10时44分，《太平洋：给予诺诚健华买入评级，目标价位16.1元》资讯为影响诺诚健华的重要信息。首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502104409861eaa27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502104409861eaa27&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432369466","title":"诺诚健华(09969)上涨5.4%，报4.88元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432369466","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432369466?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:44","pubTimestamp":1714617846,"startTime":"0","endTime":"0","summary":"5月2日，诺诚健华(09969)盘中上涨5.4%，截至10:44，报4.88元/股，成交128.97万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2023年年报，诺诚健华营业总收入7.39亿元、净利润-6.31亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02104440509067.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431883102","title":"诺诚健华(09969.HK)将于5月13日举行董事会会议以审批第一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2431883102","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431883102?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:43","pubTimestamp":1714380185,"startTime":"0","endTime":"0","summary":"格隆汇4月29日丨诺诚健华(09969.HK)公告，公司将于2024年5月13日举行董事会会议，藉以考虑及批准公司及其附属公司截至2024年3月31日止三个月的未经审核第一季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916431487be4e6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916431487be4e6c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431307500","title":"太平洋：给予诺诚健华买入评级，目标价位16.1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431307500","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431307500?lang=zh_cn&edition=full","pubTime":"2024-04-29 13:02","pubTimestamp":1714366953,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,霍亮,戎晓婕近期对诺诚健华进行研究并发布了研究报告《血液瘤先发优势稳固，自免管线收获期临近》，本报告对诺诚健华给出买入评级，认为其目标价位为16.10元，当前股价为8.45元，预期上涨幅度为90.53%。我们分别使用DCF法和NPV法进行估值并取二者的平均数，测算出目标市值为283.73亿元人民币，对应股价为16.10元。首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291304268b604f4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291304268b604f4c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430033637","title":"诺诚健华：北京诺诚健华医药科技有限公司科学技术协会成立，推动科技进步","url":"https://stock-news.laohu8.com/highlight/detail?id=2430033637","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430033637?lang=zh_cn&edition=full","pubTime":"2024-04-28 09:51","pubTimestamp":1714269105,"startTime":"0","endTime":"0","summary":"【2024年4月27日，北京诺诚健华医药科技有限公司科学技术协会正式挂牌成立，旨在推进科技创新与产学研深度融合。】 在昌平区科学技术协会的引领下，诺诚健华科学技术协会正式成立。诺诚健华旨在通过科技创新，推动产业链各环节形成合力，共同进步。诺诚健华，作为一家商业化阶段的生物医药高科技公司，专注于恶性肿瘤及自身免疫性疾病领域的一类新药研制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281002158b5c403a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281002158b5c403a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430748222","title":"诺诚健华连续第五年发布ESG报告 首次设定未来五年环境管理目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2430748222","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2430748222?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:38","pubTimestamp":1714135128,"startTime":"0","endTime":"0","summary":"4月26日，诺诚健华发布2023年环境、社会和公司治理（ESG）报告，这也是公司连续第五年发布ESG报告，并首次在报告中设定未来五年具体的环境管理目标。诺城健华在今年的ESG报告中指出，到2028年，公司温室气体排放强度、能源使用强度、工业废水排放强度将在2023年的基础上分别降低10%，废气排放处理合规率和废弃物处理合规率将分别为100%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263061464381.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430440195","title":"诺诚健华ICP-248新药亮相：奥布替尼获北京市专利一等奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2430440195","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430440195?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:01","pubTimestamp":1714039305,"startTime":"0","endTime":"0","summary":" 诺诚健华携其最新研发成果亮相4月25日至29日在北京举办的2024中关村论坛年会，并参与多个论坛和闭门会。在国际技术交易大会上，该公司首次公开展示了其自主研发的新型口服高选择性BCL2抑制剂ICP-248。奥布替尼作为国家“重大新药创制”专项成果，已在中国和新加坡获批上市，并在中国获批三项适应症，纳入中国国家医保。4月25日，在中关村论坛全球知识产权保护与创新论坛上，奥布替尼核心专利荣获第七届北京市发明专利奖一等奖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251934138b52dc45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251934138b52dc45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430788804","title":"诺诚健华连续亮相中关村论坛 高质量创新赋能新质生产力发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2430788804","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430788804?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:19","pubTimestamp":1714033179,"startTime":"0","endTime":"0","summary":"2024年4月25日，中国北京——2024中关村论坛年会于4月25日至29日在北京举办。作为一家生物医药高科技公司，诺诚健华（上交所代码：688428；香港联交所代码：09969）以“科学驱动创新”为发展理念，携最新研发成果连续亮相中关村论坛，以高质量创新为新质生产力蓄势赋能，同时参与多个论坛和闭门会与社会各界共同为论坛主题“创新：建设更加美好的世界”献计献策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404253059319668.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404253059319668.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430420338","title":"诺诚健华04月25日获主力加仓76万元 环比增加590.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430420338","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430420338?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:16","pubTimestamp":1714033004,"startTime":"0","endTime":"0","summary":"04月25日, 诺诚健华股价涨1.39%，报收4.39元，成交金额993万元，换手率0.15%，振幅3.46%，量比0.51。诺诚健华今日主力资金净流入76万元，上一交易日主力净流入11万元，今日环比增加590.91%。该股近5个交易日上涨2.09%，主力资金累计净流出50万元；近20日主力资金累计净流入495万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516175487ae3e19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516175487ae3e19&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430427644","title":"诺诚健华连续亮相中关村论坛，高质量创新赋能新质生产力发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2430427644","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430427644?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:15","pubTimestamp":1714032900,"startTime":"0","endTime":"0","summary":"北京诺诚健华医药科技有限公司科学技术协会将在4月27日举办的中关村“留学人员创新创业”平行论坛上举行揭牌仪式，旨在构建完善的创新生态，持续推动科技进步。ICP-248是诺诚健华自主研发的新型口服高选择性BCL2抑制剂，首次亮相中关村论坛，参与国际技术交易大会“新技术新产品首发与推介大会”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516154387ae3b80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516154387ae3b80&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150025","title":"诺诚健华04月23日主力资金流出1万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150025","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429150025?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:16","pubTimestamp":1713860173,"startTime":"0","endTime":"0","summary":"04月23日, 诺诚健华股价涨0.48%，报收4.22元，成交金额1559万元，换手率0.25%，振幅5.48%，量比0.75。诺诚健华今日主力资金净流出1万元，连续3日净流出，上一交易日主力净流出85万元，今日环比减少98.82%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为53.33%，平均跌幅为2.35%。该股近5个交易日下跌7.47%，主力资金累计净流入331万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入167万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316164087a531b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316164087a531b5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429618730","title":"南向资金4月22日净买入诺诚健华132.10万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429618730","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429618730?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:31","pubTimestamp":1713835875,"startTime":"0","endTime":"0","summary":"4月22日, 南向资金增持诺诚健华132.10万股，连续7日增持。截止当日收盘，港股通共持有诺诚健华22325.89万股，占流通股12.65%。诺诚健华近5个交易日下跌11.02%，港股通累计增持539.80万股；近20个交易日下跌13.04%，港股通累计增持958.00万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309475987a38983&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309475987a38983&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428063331","title":"诺诚健华：公司的研发与经营截至目前一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2428063331","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428063331?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:36","pubTimestamp":1713515814,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好！近期诺诚健华股价A股持续下跌，大幅破发。请问公司是出现了什么问题吗？希望能通过回购等措施保护投资者权益，这既可以维护公司形象，给投资人信心，也有利于行业持续发展。谢谢！诺诚健华（688428.SH）4月19日在投资者互动平台表示，公司的研发与经营截至目前一切正常。二级市场受多种因素影响，请注意投资风险。文章来源：每日经济新闻原标题：诺诚健华：公司的研发与经营截至目前一切正常","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191649218b3a4224&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191649218b3a4224&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428508948","title":"诺诚健华盘中异动 大幅下跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428508948","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428508948?lang=zh_cn&edition=full","pubTime":"2024-04-19 11:03","pubTimestamp":1713495812,"startTime":"0","endTime":"0","summary":"2024年04月19日早盘11时03分，诺诚健华股票出现异动，股价急速下挫5.10%。截至发稿，该股报4.090港元/股，成交量152.694万股，换手率0.10%，振幅4.87%。诺诚健华股票所在的生物技术行业中，整体跌幅为1.22%。其相关个股中，创胜集团-B、三叶草生物-B、帝王国际投资涨幅较大，振幅较大的相关个股有三叶草生物-B、创胜集团-B、乐普生物-B，振幅分别为12.70%、12.50%、9.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041911033287e820a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041911033287e820a1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428551448","title":"诺诚健华04月18日主力资金流入327万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428551448","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428551448?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:15","pubTimestamp":1713428154,"startTime":"0","endTime":"0","summary":"04月18日, 诺诚健华股价跌3.58%，报收4.31元，成交金额2713万元，换手率0.42%，振幅4.70%，量比0.81。诺诚健华今日主力资金净流入327万元，连续3日净流入，上一交易日主力净流入141万元，今日环比增加131.91%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为33.33%，平均涨幅为1.23%。该股近5个交易日下跌11.86%，主力资金累计净流入589万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入79万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616208b34bdb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616208b34bdb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427186950","title":"诺诚健华(09969)下跌5.0%，报4.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427186950","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427186950?lang=zh_cn&edition=full","pubTime":"2024-04-15 10:01","pubTimestamp":1713146517,"startTime":"0","endTime":"0","summary":"4月15日，诺诚健华(09969)盘中下跌5.0%，截至10:01，报4.75元/股，成交242.62万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2023年年报，诺诚健华营业总收入7.39亿元、净利润-6.31亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/15100140236354.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425067730","title":"诺诚健华(9969.HK)：业绩符合预期 多产品即将提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2425067730","media":"国泰君安","top":-1,"share":"https://www.laohu8.com/m/news/2425067730?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:01","pubTimestamp":1712534501,"startTime":"0","endTime":"0","summary":"本报告导读：2023 年奥布替尼营收6.71 亿元，血液瘤、自免、实体瘤临床进展顺利，2024 年多款药物有望提交NDA，看好公司未来发展，维持“增持”评级。公司公告 2023年收入 7.39 亿，同比增长 18.1%；净亏损6.31 亿元，同比减亏2.56 亿元。奥布替尼快速放量，多适应症今年内有望递交NDA。④ICP-723 的晚期实体瘤注册临床试验加速推进，预计2024 年底或2025 年初递交NDA。⑤ICP-189联合三代EGFR 抑制剂伏美替尼治疗晚期实体瘤完成首例患者入组，预计2024 年获得PoC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080801448afc3db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080801448afc3db8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425062370","title":"诺诚健华盘中异动 早盘股价大跌5.11%报4.640港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425062370","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425062370?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:01","pubTimestamp":1712282474,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘10时01分，诺诚健华股票出现异动，股价急速跳水5.11%。截至发稿，该股报4.640港元/股，成交量17.3万股，换手率0.01%，振幅5.32%。资金方面，该股资金流入13.634万港元，流出51.935万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为1.19%。该信息摘要如下：近日， 诺诚健华 发布2023年年度报告。去年，诺诚健华的整体业绩良好，其自主研发的首款商业化拳头产品奥布替尼可谓功不可没。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405100115791ed36a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405100115791ed36a&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.1936},{"period":"1month","weight":0.0826},{"period":"3month","weight":0.0295},{"period":"6month","weight":-0.1643},{"period":"1year","weight":-0.4032},{"period":"ytd","weight":-0.2395}],"compareEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0753},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0307},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":0.068}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、伊布替尼、泽布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-192、ICP-723和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.120109},{"month":2,"riseRate":0.5,"avgChangeRate":0.019126},{"month":3,"riseRate":0,"avgChangeRate":-0.043789},{"month":4,"riseRate":0.6,"avgChangeRate":0.117148},{"month":5,"riseRate":0.2,"avgChangeRate":-0.033024},{"month":6,"riseRate":0.75,"avgChangeRate":0.124297},{"month":7,"riseRate":0.5,"avgChangeRate":-0.026188},{"month":8,"riseRate":0,"avgChangeRate":-0.125366},{"month":9,"riseRate":0,"avgChangeRate":-0.152637},{"month":10,"riseRate":0.5,"avgChangeRate":0.014569},{"month":11,"riseRate":1,"avgChangeRate":0.145409},{"month":12,"riseRate":0.75,"avgChangeRate":0.038159}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}